Market closedNon-fractional
Immunic/IMUX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Ticker
IMUX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
80
Website
imux.com
Immunic Metrics
BasicAdvanced
$125M
Market cap
-
P/E ratio
-$1.70
EPS
1.93
Beta
-
Dividend rate
Price and volume
Market cap
$125M
Beta
1.93
Financial strength
Current ratio
5.094
Quick ratio
4.902
Long term debt to equity
0.518
Total debt to equity
1.352
Management effectiveness
Return on assets (TTM)
-56.24%
Return on equity (TTM)
-112.05%
Valuation
Price to book
1.5
Price to tangible book (TTM)
1.5
Price to free cash flow (TTM)
-1.062
Growth
Earnings per share change (TTM)
-51.50%
3-year earnings per share growth (CAGR)
-23.81%
What the Analysts think about Immunic
Analyst Ratings
Majority rating from 5 analysts.
Immunic Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$30M
37.21%
Profit margin
0.00%
NaN%
Immunic Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.51
-$0.48
-$0.30
-
Expected
-$0.52
-$0.55
-$0.51
-$0.26
-$0.23
Surprise
3.05%
-6.85%
-6.48%
15.38%
-
Immunic News
AllArticlesVideos
Immunic appoints Simona Skerjanec to board of directors
Proactive Investors·2 days ago
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
PRNewsWire·3 days ago
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
Proactive Investors·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunic stock?
Immunic (IMUX) has a market cap of $125M as of July 27, 2024.
What is the P/E ratio for Immunic stock?
The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of July 27, 2024.
Does Immunic stock pay dividends?
No, Immunic (IMUX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Immunic dividend payment date?
Immunic (IMUX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunic?
Immunic (IMUX) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Immunic stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.